The risk of febrile seizures following influenza and 13-valent pneumococcal conjugate vaccines. Issue 9 (24th February 2020)

• Record Type: Journal Article
• Authors: Baker, Meghan A.; Jankosky, Christopher; Yih, W. Katherine; Gruber, Susan; Li, Lingling; Cocoros, Noelle M.; Lipowicz, Hana; Coronel-Moreno, Claudia; DeLuccia, Sandra; Lin, Nancy D.; McMahill-Walraven, Cheryl N.; Menschik, David; Selvan, Mano S.; Selvam, Nandini; Chen Tilney, Rong; Zichittella, Lauren; Lee, Grace M.; Kawai, Alison Tse
• Is Part Of: Vaccine. Volume 38:Issue 9(2020)
• Page Start: 2166
• Page End: 2171
• Publication Date: 2020-02-24
• Subjects: Febrile seizure -- 13-valent pneumococcal conjugate vaccine -- PCV13 -- Influenza vaccine; Vaccines -- Periodicals; 615.372
• DOI: 10.1016/j.vaccine.2020.01.046
• Languages: English
• ISSNs: 0264-410X

Abstract

Highlights: Elevated risk of febrile seizures after PCV13 vaccine but not after influenza vaccine. Risk of febrile seizures after PCV13 low compared to overall risk in this population. No clear evidence for elevated risk after concomitant vaccination. Abstract: Background: Evidence on the risk of febrile seizures after inactivated influenza vaccine (IIV) and 13-valent pneumococcal conjugate vaccine (PCV13) is mixed. In the FDA-sponsored Sentinel Initiative, we examined risk of febrile seizures after IIV and PCV13 in children 6–23 months of age during the 2013–14 and 2014–15 influenza seasons. Methods: Using claims data and a self-controlled risk interval design, we compared the febrile seizure rate in a risk interval (0–1 days) versus control interval (14–20 days). In exploratory analyses, we assessed whether the effect of IIV was modified by concomitant PCV13 administration. Results: Adjusted for age, calendar time and concomitant administration of the other vaccine, the incidence rate ratio (IRR) for risk of febrile seizures following IIV was 1.12 (95% CI 0.80, 1.56) and following PCV13 was 1.80 (95% CI 1.29, 2.52). The attributable risk for febrile seizures following PCV13 ranged from 0.33 to 5.16 per 100, 000 doses by week of age. The age and calendar-time adjusted IRR comparing exposed to unexposed time was numerically larger for concomitant IIV and PCV13 (IRR 2.80, 95% CI 1.63, 4.83), as compared to PCV13 without concomitant IIV (IRR 1.54, 95% CI 1.04, 2.28), and the IRR for IIV without concomitant PCV13 suggested no independent effects of IIV (IRR 0.94, 95% CI 0.63, 1.42). Taken together, this suggests a possible interaction between IIV and PCV13, though our study was not sufficiently powered to provide a precise estimate of the interaction. Conclusions: We found an elevated risk of febrile seizures after PCV13 vaccine but not after IIV. The risk of febrile seizures after PCV13 is low compared to the overall risk in this population of children, and the risk should be interpreted in the context of the importance of preventing pneumococcal infections.